Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL15135686 | 0.96 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP3A4KDM4EALDH1A1RECQL | |
| SCHEMBL967441 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 | |
| SCHEMBL970571 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 | |
| SCHEMBL12391998 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 | |
| SCHEMBL970017 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 | |
| SCHEMBL9592076 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 | |
| SCHEMBL4254052 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4KDM4EALDH1A1RECQL | |
| SCHEMBL9818198 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4KDM4EALDH1A1RECQL | |
| SCHEMBL79031 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4KDM4EALDH1A1RECQL | |
| SCHEMBL9590081 | 0.86 | HRH3 (0.56) | SMN1; SMN2CYP3A4KDM4EALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020995-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | Mallinckrodt Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007133583-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | MALLINCKRODT INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| CN-118829433-A | Respiratory stimulant parenteral formulations | 依那拉治疗股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118488840-A | Methods of treating respiratory depression modulated by non-opioid agents | 依那拉治疗股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226007-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-07-11 | — | — | US | disclosed |
| EP-4333807-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333852-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Enalare Therapeutics Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117529306-A | Nicotinamide Adenine Dinucleotide (NAD) compositions, methods of making and methods of using the same | 索维达解决方案有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117479945-A | Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same | 依那拉治疗股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-0162975-B1 | P-ALKYL OR CYCLOALKYL PHENOXY ALKANOLS AND ALKANOL ESTERS AND USE FOR THE TREATMENT OF ALLERGIC CONDITIONS | PHARMACO DEVELOPMENT PARTNERS (US) | 1988-07-27 | — | — | EP | disclosed |
| EP-0162975-A1 | P-alkyl or cycloalkyl phenoxy alkanols and alkanol esters and use for the treatment of allergic conditions | PHARMACO DEVELOPMENT PARTNERS (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4543362-A | P-Alkyl or cycloalkyl phenoxy alkanols and alkanol esters and process for the treatment of allergic conditions | Berger, Frank M. (US) | 1985-09-24 | — | — | US | disclosed |
| US-4504412-A | Cyclohexane derivatives in fragrance compositions | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
| US-4451474-A | T-Butyl-phenoxy-alkylene esters of benzoic and nicotinic acids, compositions containing same and their antihistaminic method of use | Berger, Frank M. (US) | 1984-05-29 | — | — | US | disclosed |
| US-4388081-A | CONTAINING PHENOXYALCOHOL AS ANTINKNOCK ADDITIVE | PHILLIPS PETROLEUM COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
| US-4255152-A | USING A DISPERSE DYE, WATER, AND AN ADDUCT OF ETHYLENE, PROPYLENE, OR STYRENE OXIDE AND A CYCLIC-SUBSTITUTED PHENOL; LEVELLING | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4238625-A | ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
| US-4125732-A | HYPOLIPIDEMIC | AMERICAN CYANAMID COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | SMN1; SMN2 3228/4885CYP3A4 84/4885KDM4E 3072/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | SMN1; SMN2 630/4885CYP3A4 2106/4885KDM4E 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.